Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NRX Pharmaceuticals, Inc. - Common Stock
(NQ:
NRXP
)
2.360
-0.080 (-3.28%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NRX Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
December 03, 2025
Via
Get News
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment
December 03, 2025
Via
Investor Brand Network
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
December 03, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
FDA Submission for Abbreviated New Drug Application; $750 Million Market for Suicidal Depression Market Awaits Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
December 02, 2025
Via
Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date
December 02, 2025
Via
Investor Brand Network
NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2
December 02, 2025
Via
Investor Brand Network
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
December 02, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
December 02, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at NobleCon21
December 01, 2025
Via
Investor Brand Network
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
December 01, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
New to The Street Show #702 Airs Today on Bloomberg at 6:30 PM EST
November 22, 2025
Via
ACCESS Newswire
Three Revenue-Generating Facilities in Florida Plus Six More by Year-End in Expanding $750 Million Market Suicidal Depression Market: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
November 17, 2025
Via
Get News
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs
November 17, 2025
Via
Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 17, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17
November 12, 2025
Via
Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
November 12, 2025
Via
Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
November 12, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
$750 Million Market On Track to $3.35 Billion by 2034 Has High Return Opportunity with First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health: NRXP
November 10, 2025
Via
Get News
MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida
November 10, 2025
Via
Investor Brand Network
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
November 10, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market
October 24, 2025
Via
Investor Brand Network
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
October 20, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
MissionIRNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs
October 16, 2025
Via
Investor Brand Network
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
October 16, 2025
Via
Investor Brand Network
New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group
October 11, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies
October 08, 2025
Via
Investor Brand Network
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition
October 07, 2025
Via
Investor Brand Network
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
October 06, 2025
Via
Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
October 06, 2025
From
NRx Pharmaceuticals, Inc.
Via
GlobeNewswire
$750 Million Market Projected to Reach $3.35 Billion in 2034; Mega Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
September 29, 2025
Via
Get News
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.